期刊文献+

抗衰灵与多奈哌齐治疗阿尔茨海默氏病疗效比较 被引量:2

Kangshuailing Capsule and Donepezil on Treating Alzheimer's Disease
下载PDF
导出
摘要 目的:观察自制中药制剂"抗衰灵胶囊"合多奈哌齐治疗阿尔茨海默氏病(AD)的临床疗效。方法:对AD患者257例分别用"抗衰灵胶囊"(治疗组)与盐酸多奈哌齐片(对照组)进行随机对照观察,疗程8周。结果:治疗后治疗组患者简明精神状态检查表(MMSE)、长谷川痴呆量表(HDS)评分均较治疗前明显增加;对治疗前后精神症状量表(PRS)评分及血液流变学指标变化的观察,在改善患者精神症状及某些血液流变学指标方面治疗组略优于对照组;日常生活能力量表(ADL)评分治疗前后无明显变化;治疗组显效率32.0%,有效率68.8%;对照组分别为34.4%和69.5%,两组比较,差异无统计学意义。结论:"抗衰灵胶囊"对轻、中度AD患者有良好治疗效果,且无严重不良反应,其改善大脑微循环作用可能是"抗衰灵胶囊"治疗AD的机制之一。 Objectlve:To observe the clinical curative effect of Kangshuailing capsule and Donepezil on treating Alzheimer disease (AD). Methods:257 cases of AD were randomly divided into the treatment group and the contrast group. The treatment group was treated by Kangshuailing capsule and the contrast group by Donepezil respectively. The period of therapy was 8 weeks. Results: The scores of MMSE and HDS in the treatment group were obviously improved after therapy. The score of PRS and several index of blood rheology in the treatment group was better than that in the contrast group. The score of ADL had no obvious difference. The significant effective ratio and the effective ratio in the treatment group was 32.0% and 68.8% respectively. The significant effective ratio and the effective ratio in the contrast group was 34.4% and 69.5% respectively. There was no statistic meaning. Conclusion:Kangshuailing capsule has good effect on treating mild and moderate AD and has no serious side effect. One of its mechanism maybe it can improve the microcirculation of brain.
出处 《浙江中西医结合杂志》 2007年第11期663-664,667,共3页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
关键词 阿尔茨海默氏病 抗衰灵胶囊 盐酸多奈哌齐 血液流变 疗效分析 Alzheimer's disease Kangshuailing capsule blood rheology curative effect analysis
  • 相关文献

参考文献6

二级参考文献14

  • 1张明园.量表在痴呆诊断中的应用[J].实用内科杂志,1993,13(6):337-339. 被引量:76
  • 2廖方正,李青.脑力康对老年痴呆病的疗效观察──附:31例病例报告[J].成都中医药大学学报,1996,19(1):20-23. 被引量:23
  • 3Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol. 1996 ;29(2-3):237~52.
  • 4Emilien G, Beyreuther K, Masters CL, et al. Prospects for pharmacological intervention in Alzheimer disease [J]. Arch Neurol,2000,57(4): 454~459.
  • 5Lyudmila V, Boroviko VA, Svetlanal, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.Nature, 2000,405:458~461.
  • 6Kelles A, Janssens J, Tack J. IL-lbeta and IL-6 excite neurones and suppress cholinergic neurotransmission in the myenteric plexus of the guinea pig. Neurogastroenterol Motit. 2000; 12(6):531~8.
  • 7Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging, 1996.17(5) :673.
  • 8Li Y, Liu L, Kang J, et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci. 2000;20(1): 149~55.
  • 9Gambi F, Reale M, Iarlori C, et al. Alzheimer patients treated with an Ache inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol. 2004;24(3):314~21.
  • 10Perry EK, Perry RⅡ, BLessed G, et al. Necropsy evidence of central cholinergic deficits in senile dementia[J]. Lancet, 1977,189-194.

共引文献12

同被引文献61

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部